Ralliant Corporation (NYSE:RAL) Receives $75.70 Consensus Price Target from Analysts

Shares of Ralliant Corporation (NYSE:RAL) have received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $75.70.

RAL has been the subject of several research reports. Oppenheimer increased their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on Ralliant from $71.00 to $73.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. BMO Capital Markets assumed coverage on Ralliant in a report on Monday, July 20th. They issued a “market perform” rating and a $78.00 price target for the company. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a report on Friday, July 31st.

Ralliant Price Performance

Shares of Ralliant stock opened at $63.72 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The firm has a fifty day moving average price of $68.94 and a two-hundred day moving average price of $55.94. The company has a market cap of $7.05 billion, a PE ratio of -5.87, a price-to-earnings-growth ratio of 2.36 and a beta of 1.61.

Ralliant (NYSE:RAL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts expect that Ralliant will post 2.87 EPS for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s dividend payout ratio is presently -1.84%.

Insider Buying and Selling at Ralliant

In related news, CEO Tamara S. Newcombe sold 12,936 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the transaction, the chief executive officer directly owned 251,967 shares of the company’s stock, valued at $18,088,710.93. This trade represents a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of Ralliant stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the sale, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. This represents a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is owned by company insiders.

Institutional Trading of Ralliant

Several institutional investors have recently made changes to their positions in RAL. BlackRock Inc. bought a new position in Ralliant during the second quarter worth about $1,039,481,000. Viking Global Investors LP acquired a new stake in Ralliant during the second quarter valued at approximately $257,200,000. State Street Corp bought a new stake in shares of Ralliant in the 2nd quarter valued at approximately $213,096,000. Millennium Management LLC grew its stake in shares of Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. Finally, Flossbach Von Storch SE bought a new stake in shares of Ralliant in the 2nd quarter valued at approximately $222,460,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.